Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 776,985Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 16Amitiza

PharmaCompass

01

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 272

2018 Revenue in Millions : 305

Growth (%) : -11

blank

02

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 236

2019 Revenue in Millions : 277

Growth (%) : -15

blank

03

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 189

2019 Revenue in Millions : 209

Growth (%) : -9

blank

04

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 197

2020 Revenue in Millions : 189

Growth (%) : 4

blank

05

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 70

2020 Revenue in Millions : 227

Growth (%) : -67

blank

06

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 159

2021 Revenue in Millions : 197

Growth (%) : -19

blank

07

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 168

2021 Revenue in Millions : 202

Growth (%) : -17

blank

08

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 5

2021 Revenue in Millions : 70

Growth (%) : -93

blank

09

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2023 Revenue in Millions : 157

2022 Revenue in Millions : 168

Growth (%) : -6

blank

10

Brand Name : Amitiza

Lubiprostone

arrow
Antibody Engineering
Not Confirmed

Brand Name : Amitiza

arrow
Antibody Engineering
Not Confirmed

Lubiprostone

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2023 Revenue in Millions : 77

2022 Revenue in Millions : 159

Growth (%) : -51

blank